NCT04213599 is a clinical trial of Coronary intervention in ST-Elevation Myocardial Infarction, sponsored by Xiamen Cardiovascular Hospital, Xiamen University.

Who is sponsoring NCT04213599?

NCT04213599 is sponsored by Xiamen Cardiovascular Hospital, Xiamen University.

What drugs are being tested in NCT04213599?

Interventions in NCT04213599: Coronary intervention.

What condition does NCT04213599 study?

NCT04213599 studies ST-Elevation Myocardial Infarction.

Is NCT04213599 still recruiting?

NCT04213599 is currently status unknown. Last updated 2 January 2020.

Last reviewed 2020-01-02 · How we verify

NCT04213599

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Angiography Characteristic of Free Wall Ruptrue in STEMI

Status unknown Last updated 2 January 2020

What this trial tests

trial testing Coronary intervention in ST-Elevation Myocardial Infarction in 14,629 participants. Status unknown.

Timeline

1 January 2011

Primary endpoint
31 August 2020

30 September 2020

Quick facts

Lead sponsor	Xiamen Cardiovascular Hospital, Xiamen University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	14,629
Start date	1 January 2011
Primary completion	31 August 2020
Estimated completion	30 September 2020
Sites	1 location across China

Drugs / interventions tested

Coronary intervention

Conditions studied

ST-Elevation Myocardial Infarction — all drugs for ST-Elevation Myocardial Infarction →

Sponsor

Xiamen Cardiovascular Hospital, Xiamen University

Who can join

18 and older, any sex, with ST-Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To analyze whether the location of myocardial infarction and infarct related artery are related to FWR.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Coronary intervention

Trials testing the same drug.

NCT05705102 — Time for a Paradigm Shift: STEMI/NSTEMI to OMI/NOMI ? · terminated
NCT02316886 — Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque · Phase 4 · completed

Other recruiting trials for ST-Elevation Myocardial Infarction

Currently open trials in the same condition.

NCT07444957 — Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease · recruiting

Other Xiamen Cardiovascular Hospital, Xiamen University trials

Trials by the same sponsor.

NCT07055919 — Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER). · NA · recruiting
NCT06532838 — Optimized Strategies for Malperfusion Syndrome · NA · not yet recruiting
NCT05925335 — The China Mviv Registry · NA · unknown
NCT05497141 — Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Sever · NA · unknown
NCT04918030 — STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease（ · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04213599 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiamen Cardiovascular Hospital, Xiamen University
Last refreshed: 2 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04213599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing